WP
ACET icon

Woodline Partners’s Adicet Bio ACET Stock Holding History

Woodline Partners’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.13M Sell
313,124
-311,876
-50% -$2.33M 0.01% 800
2025
Q4 		$5.26M Buy
+625,000
New +$6.91M 0.02% 616
2024
Q3 		– Sell
-30,381
Closed -$588K – 588
2024
Q2 		$588K Sell
30,381
-15,562
-34% -$417K 0.01% 492
2024
Q1 		$1.73M Buy
+45,943
New +$1.9M 0.02% 434
2022
Q2 		– Sell
-12,282
Closed -$3.92M – 794
2022
Q1 		$3.92M Buy
+12,282
New +$2.82M 0.06% 272

Other funds holding ACET

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Woodline Partners's ACET Position: Q1 2026 in Review

Woodline Partners reduced its Adicet Bio (ACET) stake by 50% in Q1 2026, selling an estimated $2.33M and leaving 313,124 shares worth $2.13M. The position accounts for 0.01% of the portfolio, ranked #800.

Woodline Partners first reported a position in ACET in Q1 2022 and has held it in 5 quarters since. The position peaked at $5.26M in Q4 2025. 49 funds tracked by Wall St. Rank hold ACET as of Q1 2026.

  • Woodline Partners held 313,124 shares of Adicet Bio worth $2.13M as of Q1 2026.
  • Woodline Partners sold 311,876 Adicet Bio shares in Q1 2026, an estimated $2.33M.
  • Adicet Bio made up 0.01% of Woodline Partners's portfolio in Q1 2026, its #800 holding.
  • Woodline Partners first reported a position in Adicet Bio in Q1 2022 and has held it in 5 quarters since.
  • Woodline Partners's Adicet Bio position peaked at $5.26M in Q4 2025.
  • 49 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.